07:38 AM EDT, 09/30/2024 (MT Newswires) -- BioCryst Pharmaceuticals ( BCRX ) said Monday it has been awarded a US Department of Health and Human Services contract worth up to $69 million over five years to provide up to 95,625 doses of Rapivab for the treatment of influenza.

Under the contract, BioCryst will supply injections to the Center for the Strategic National Stockpile for an initial 12 months, with four optional 12-month ordering periods. The company said it plans to provide 19,125 shots by next September for $13.9 million.

Price: 7.70, Change: +0.08, Percent Change: +1.05